2nd Annual CMIE Conference on Medical Isotopes

December 11-12 2025
Sheraton Toronto Airport Hotel & Conference Centre
801 Dixon Rd, Toronto, ON M9W 1J5

SPEAKERS

Bill Dickie
Senior Life Sciences Leader

30+ years’ experience in leadership roles with life sciences companies. President and CEO of Advanced Proteome Therapeutics (TMX:APC), Co-founder, President, CEO and Director of Atreus Pharmaceuticals, acquired by Advanced Accelerator Applications International, a Novartis company. President, CEO and Director of Liponex Inc., (TSX:LPX). Multiple executive roles with MDS Nordion Inc. in the radiopharmaceutical and medical software businesses.

Lana Janes
Chief Operating Officer, Abdera Therapeutics

Lana Janes is Chief Operating Officer at Abdera Therapeutics and has more than 20 years of public and private company management and operations experience that spans the full life cycle of therapeutic product development.

Lana is a co-founder of Abdera Therapeutics, having led the incubation and spin-out of the company from adMare Bioinnovations where she was a venture partner. Prior to that, Lana served as chief patent officer of QLT Inc. where, for 12 years, she was responsible for all aspects of global intellectual property and strategic life cycle management for FDA-approved products Visudyne®, Aczone® and Eligard®, as well as numerous preclinical and clinical-stage pharmaceutical products across multiple therapeutic areas. She also served as SVP of Technology Development in her later years at QLT, where she led the R&D organization and oversaw clinical development of the company’s late-stage ophthalmology assets.

Prior to that, Lana worked as a registered Canadian and U.S. patent agent in the Toronto office of Ogilvy Renault LLP (now Norton Rose Fulbright) and at F. Hoffman-La Roche in Basel, Switzerland, where her practice focused on strategic IP protection for numerous therapeutic and medical device franchises.

Lana sits on the boards of Life Sciences British Columbia and the Centre for Probe Development and Commercialization (CPDC) in Ontario.

Lana received her A.B. in chemistry with honors from Harvard University and her Ph.D. with honors in biological organic chemistry from McGill University, where she also conducted her postdoctoral work in the field of antiviral therapeutics.

Keith Ladouceur
Director of Technology Development, TRIUMF Innovations

Keith Ladouceur is the Director of Technology Development at TRIUMF Innovations where he oversees research and development programs, finds new commercial opportunities for TRIUMF technologies, and provides business development support to TRIUMF researchers.

Keith has held various roles at TRIUMF Innovations, translating his background in science towards business development and creating bridges between academia and industry. He has helped to secure more than $20M in funding for research and commercialization projects and worked on transitioning multiple TRIUMF technologies to successful spin-off companies.

Chad MacLean
Senior Director, Business Development & Transformation, Bruce Power

Chad grew up in Brampton Ontario, and joined Bruce Power in 2011, starting out with the company as the Manager of Bruce Power’s radioactive waste management program. Chad then spent the next 5 years as a member of the Senior Leadership Team at the Bruce B station, where he held the role of Chemistry & Environment Manager, along with spending time in Operations leading the Fuel Handling, Dry Fuel Storage and Isotope handling teams. After supporting the successful completion of the defuel campaign for Bruce Power’s first Major Component Replacement in Unit 6, Chad moved over to join the Business Development & Transformation team. 

In his current role, Chad leads efforts in Bruce Power’s nuclear expansion strategy, including increasing output from the existing 8 reactors onsite, along with new build planning activities for Bruce C. Additionally, and noted as one of his proudest accomplishments, Chad has oversight of Bruce Power’s medical isotope and irradiation services program.

As a representative of Bruce Power, Chad is an active board member of the Nuclear Innovation Institute, and has participated in CSA and Conexus committees and sub-committees, while also serving on the Southwestern Isotope Coalition Advisory Committee. Chad is also proud to participate as a mentor through the Easter Seals Program.

Don Richardson, Ph.D
CEO, Minogi Corp. / Interim CEO, Noozhoo Nokiiyan LP / First Nation Consultation Advisor

Don has 30 years experience building agreements between First Nation governments and economic development corporations, project proponents, and Crown agencies, together with extensive global experience with environmental assessments, socio-economics, traditional ecological knowledge, and enhancing community well-being. Don optimizes economic development and environmental protection for major projects, thereby supporting First Nation ownership and co-development. Areas of expertise include economic development & partnership structuring, business planning, and project impact assessment. Sectors include energy, nuclear, mining, and infrastructure development projects. Don has been working for the Mississaugas of Scugog Island First Nation for 3 years.

Owen Roberts
CEO, CPDC

Owen Roberts joined CPDC in October 2022 as CEO bringing over 20 years of biotech executive experience to his role at CPDC. A serial biotech entrepreneur, Owen was most recently the founder and CEO of Nobelex Biotech Inc., a Canadian biotech contract research organization focused on discovering and developing antibiotics to treat bacterial infections caused by drug-resistant bacteria.

Ben Rotstein
Associate professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa, Director of the Molecular Imaging Probes and Radiochemistry Laboratory

Dr. Rotstein is an associate professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa, and director of the Molecular Imaging Probes and Radiochemistry Laboratory. His research is directed towards the discovery of radiopharmaceuticals for both studying biochemical and pharmaceutical mechanisms in living systems, and diagnosis of disease conditions.

Paul Schaffer
SVP, Research & Development, Telix Pharmaceuticals

Dr. Schaffer has over 20 years of experience in driving innovation in life sciences technology and large-scale isotope production. Prior to Telix, Dr. Schaffer was CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024), as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. He is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM® Irradiation System (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix.

Adam Schuheldler
Associate Professor at University of Ottawa, Canada Research Chair (Tier 2) in chemical biology

Dr. Shuhendler is an associate professor at the University of Ottawa and holds a Canada Research Chair (Tier 2) in chemical biology. He holds a primary appointment in the Faculty of Science, Department of Chemistry & Biomolecular Sciences, and is cross-appointed to the Department of Biology. Him and his lab are developing new molecules enabling the visualization of these early signs of disease using these medical imaging technologies. He is also the Co-Founder and CSO of Yellowbird Diagnostics, a CMIE funded company focused on the development of diagnostic imaging agents for a variety of diseases.

Karin Stephenson
Director of Nuclear Research and Education Support, McMaster University

Dr. Stephenson is the Director of Nuclear Research and Education Support at McMaster University. Dr. Stephenson has over 20 years of research and leadership experience in nuclear medicine. She previously served as Director of Discovery at the Centre for Probe Development and Commercialization, where she led the research and development of new radiopharmaceuticals for applications in oncology and neurology research. In her current role at Nuclear Operations & Facilities, Karin supports the student and faculty researchers who are pioneering nuclear discoveries at McMaster. She also serves on the Board of Directors for the Nuclear Innovation Institute and is the Chief Science Officer for the Canadian Nuclear Isotope Council.

Katherine Zukotynski
Nuclear Medicine Physician, Radiologist, Engineer 

Dr. Zukotynski completed a BASc in Engineering Science, followed by Medical school and Radiology residency through the University of Toronto. She completed Nuclear Medicine training and a Fellowship in oncologic imaging through Harvard Medical School. Subsequently, she completed a PhD in artificial intelligence (AI) applied to brain imaging through the Institute of Biomedical Engineering at the University of Toronto, while working as a radiologist and nuclear medicine physician. She was on staff for several years at Harvard Medical School, the University of Toronto and McMaster University as well as being the first woman in Nuclear Medicine to become a Professor in the history of McMaster University.

Dr. Zukotynski is certified to practice nuclear medicine and radiology in both Canada and the USA. She is also a Professional Engineer. She has received awards for teaching, mentorship and research. In 2025, she was honoured with the Lifetime Achievement Award from the American College of Nuclear Medicine for her work and contribution to the field. She is a Fellow of the Royal College of Physicians and Surgeons of Canada, and has been elected as a Fellow of the American College of Nuclear Medicine, and a Fellow of the Society of Nuclear Medicine and Molecular Imaging.